Skip to content
Companies

Illexcor

Oral drug for sickle cell disease

Raised to date

$1M

of $2M offered across 1 Form D filing

Still open
$1M
Investors
1
Last filed
Mar 24, 2025

About

Illexcor Therapeutics, LLC is a biopharmaceutical company dedicated to innovating treatments for sickle cell disease (SCD). Founded in 2020, the company has a mission to address the urgent unmet medical needs by developing oral therapies that effectively manage SCD on a global level.

Illexcor stands out by focusing on first-in-class oral therapies that directly target the underlying causes of sickle cell disease, offering a potentially more accessible alternative to invasive treatments like bone marrow transplants.

Funding

  • Security to be acquiredFiled Mar 24, 2025Form D
    $1M/ $2M

Product

ILX002

Oral therapy

ILX002 is Illexcor Therapeutics' lead drug candidate designed as a first-in-class oral medication that directly combats the causes of sickle cell disease. It operates by binding to hemoglobin S, effectively preventing the polymerization that leads to the sickling of red blood cells, even under low oxygen conditions.

  • Targets hemoglobin S to prevent polymerization
  • Inhibits sickling of red blood cells
  • Proven efficacy in preclinical studies

Built for

Patients with sickle cell disease

People on file